Organogenesis acquires NuTech Medical biologics division

130
NuTech’s spine products will be sold under a new company, NuSpine

Organogenesis is expanding beyond wound care with the acquisition of has acquired NuTech Medical’ biologics section in a move intended to expand the company’s focus from wound care. 

According to a press release, the newly-combined company will offer a portfolio of advanced and next-generation products for the wound care and surgical biologics markets. NuTech Medical’s non-biologics product line will remain as a separate company, NuTech Spine.

NuTech Medical will continue existing operations as a new division of Organogenesis, focused on the surgical biologics arena.  It will continue to develop and distribute NuTech’s product line from its existing facilities in Birmingham, USA, with plans to grow its existing surgical sales network of approximately 150 representatives. NuTech’s president and chief executive officer, Howard Walthall, will join Organogenesis as president of the company’s Surgical Division, and as senior vice president for Strategy and Development for the company.